Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, Stephen L. Hauser, David Li et al.|The Lancet|2011Cited by 743
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Bita Fakhri et al.|The Lancet|2021Cited by 456
Effects of Curculigoside on Memory Impairment and Bone Loss via Anti-Oxidative Character in APP/PS1 Mutated Transgenic MiceLu Zhao, Ming Yin|PLoS ONE|2015Cited by 32